Effects of nanocurcumin in the treatment of non-alcoholic fatty liver disease

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 84

Inclusion Criteria

Inclusion Criteria:? Non-alcohilic fatty liver disease diagnosed by a radiologist and hepatologist using ?ultrasonography into one of three categories (mild, moderate or severe degree); Age 25–50 years; Overwight or obesity (25=BMI<35).

Exclusion Criteria

? History of alcohol consumption at the time of the study or in the past 12 months, based on ?patient confession; Diagnosed pathological conditions affecting the liver such as viral hepatitis, acute or chronic ?liver failure, cholestasis, liver transplantation, habitual abuse of nonsteroidal anti-inflammatory ?drugs, antibiotics, anti-secretory drugs cause achlorhydria within 3 months before the study, ?Corticosteroids, amiodarone, valproate, prednisone, tamoxifen, perhexiline and methotrexate, ?rapid weight loss, diabetes, heart failure, thyroid disorders, kidney disease, respiratory failure, ?psychological disorders, hereditary hemochromatosis and Wilson disease, alpha-1 antitrypsin ?deficiency, autoimmune diseases, celiac disease, use of liver fat inducer and hormonal drugs; Acute systemic disease, cystic fibrosis disease, muscular dystrophy, protein malnutrition, ?history of gastrointestinal surgery, neurological disorders, structural abnormalities of the ?gastrointestinal tract; The secondary causes of NAFLD, including drugs, surgical procedures, environmental toxins ?and total parenteral nutrition (TPN)?; Conditions lead to the physical inactivity (disability)?; Uncontrolled hypertension (>90/140 mmHg)?; Any diagnosed malignancy; Breast-feeding, pregnancy and or plan for pregnancy in the next 3 months; Professional athlete or regular exercise; Treatment with statins, antihypertensive and ursodeoxy colic acid, probiotics and ?multivitamin-mineral and antioxidant supplements during the three months prior to the ?intervention; Surgery for weight loss in the last year and weight loss program for the past three month; Taking a multivitamin-mineral and or antioxidants supplement at least once a week during the ?study; Not taking more than 10% of prescription supplements?

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
esfatin. Timepoint: At the beginning and end of intervention. Method of measurement: serum levels (ng/ml?) by Elisa.

Secondary Outcome Measures

Name	Time	Method
ALT/AST/TG/TC/HDL/LDL/FBS/FBI/HbA1C/TNF-Alpha/IL-6/hs-CRP. Timepoint: At the beginning and end of intervention. Method of measurement: Serum levels by Elisa.;Blood pressure, Body composition, Body Mass Iindex, Waist Circumference. Timepoint: At the beginning and end of intervention. Method of measurement: Mercury manometer, BIA, Formula, Tape measure (mmhg, %, kg/m2, cm), respectively.